Argent BioPharma (ASX:RGT) executed a further deed of variation with a fund managed by US fund manager Mercer Street Capital Partners for its convertible securities agreement, according to a Wednesday filing with the Australian bourse.
The deed includes refinancing 300,000 convertible notes totaling AU$1.6 million, the filing stated. The companies also agreed to reduce the conversion price to no less than AU$0.30 from at least AU$10.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.